{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:14:24Z","timestamp":1784268864295,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10147-024-02677-y","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T03:26:40Z","timestamp":1745378800000},"page":"1201-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Conditions for effective use of liposomal irinotecan with fluorouracil and leucovorin in unresectable pancreatic cancer after FOLFIRINOX treatment"],"prefix":"10.1007","volume":"30","author":[{"given":"Yasuyuki","family":"Okada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6776-4609","authenticated-orcid":false,"given":"Yasushi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Shinomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Tomonari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Sogabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"2677_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pan.2014.10.001","volume":"15","author":"M Hidalgo","year":"2015","unstructured":"Hidalgo M, Cascinu S, Kleeff J et al (2015) Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology 15:8\u201318. https:\/\/doi.org\/10.1016\/j.pan.2014.10.001","journal-title":"Pancreatology"},{"key":"2677_CR2","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1097\/SLA.0000000000002734","volume":"269","author":"VP Groot","year":"2019","unstructured":"Groot VP, Gemenetzis G, Blair AB et al (2019) Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg 269:1154\u20131162. https:\/\/doi.org\/10.1097\/SLA.0000000000002734","journal-title":"Ann Surg"},{"key":"2677_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","volume":"15","author":"JP Neoptolemos","year":"2018","unstructured":"Neoptolemos JP, Kleeff J, Michl P et al (2018) Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol 15:333\u2013348. https:\/\/doi.org\/10.1038\/s41575-018-0005-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2677_CR4","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R et al (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913\u20132921. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0155","journal-title":"Cancer Res"},{"key":"2677_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS et al (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"2677_CR6","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"key":"2677_CR7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"key":"2677_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/jjco\/hyy190","volume":"49","author":"F Motoi","year":"2019","unstructured":"Motoi F, Kosuge T, Ueno H et al (2019) Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP05). Jpn J Clin Oncol 49:190\u2013194. https:\/\/doi.org\/10.1093\/jjco\/hyy190","journal-title":"Jpn J Clin Oncol"},{"key":"2677_CR9","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A et al (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310:1473\u20131481. https:\/\/doi.org\/10.1001\/jama.2013.279201","journal-title":"JAMA"},{"key":"2677_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A et al (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388:248\u2013257. https:\/\/doi.org\/10.1016\/S0140-6736(16)30583-9","journal-title":"Lancet"},{"key":"2677_CR11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P et al (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011\u20131024. https:\/\/doi.org\/10.1016\/S0140-6736(16)32409-6","journal-title":"Lancet"},{"key":"2677_CR12","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M et al (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395\u20132406. https:\/\/doi.org\/10.1056\/NEJMoa1809775","journal-title":"N Engl J Med"},{"key":"2677_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M et al (2019) Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381:317\u2013327. https:\/\/doi.org\/10.1056\/NEJMoa1903387","journal-title":"N Engl J Med"},{"key":"2677_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Satake H, George TJ et al (2023) Sotorasib in KRAS p. G12C-mutated advanced pancreatic cancer. N Engl J Med 388:33\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2208470","journal-title":"N Engl J Med"},{"key":"2677_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1\u20132 trials. Lancet Oncol 21:271\u2013282. https:\/\/doi.org\/10.1016\/S1470-2045(19)30691-6","journal-title":"Lancet Oncol"},{"key":"2677_CR16","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731\u2013739. https:\/\/doi.org\/10.1056\/NEJMoa1714448","journal-title":"N Engl J Med"},{"key":"2677_CR17","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","volume":"23","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B et al (2022) Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol 23:1261\u20131273. https:\/\/doi.org\/10.1016\/S1470-2045(22)00541-1","journal-title":"Lancet Oncol"},{"key":"2677_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00494","author":"A Hendifar","year":"2021","unstructured":"Hendifar A, Blais EM, Wolpin B et al (2021) Retrospective case series analysis of RAF family alterations in pancreatic cancer: real-world outcomes from targeted and standard therapies. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.20.00494","journal-title":"JCO Precis Oncol"},{"key":"2677_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100638","volume":"7","author":"MS R\u00e9mond","year":"2022","unstructured":"R\u00e9mond MS, Pellat A, Brezault C et al (2022) Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma. ESMO Open 7:100638. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100638","journal-title":"ESMO Open"},{"key":"2677_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409\u2013413. https:\/\/doi.org\/10.1126\/science.aan6733","journal-title":"Science"},{"key":"2677_CR21","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","volume":"5","author":"EM O'Reilly","year":"2019","unstructured":"O\u2019Reilly EM, Oh DY, Dhani N et al (2019) Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol 5:1431\u20131438. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1588","journal-title":"JAMA Oncol"},{"key":"2677_CR22","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","volume":"57","author":"FM de Man","year":"2018","unstructured":"de Man FM, Goey AKL, van Schaik RHN et al (2018) Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet 57:1229\u20131254. https:\/\/doi.org\/10.1007\/s40262-018-0644-7","journal-title":"Clin Pharmacokinet"},{"key":"2677_CR23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s40265-017-0741-1","volume":"77","author":"YN Lamb","year":"2017","unstructured":"Lamb YN, Scott LJ (2017) Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma. Drugs 77:785\u2013792. https:\/\/doi.org\/10.1007\/s40265-017-0741-1","journal-title":"Drugs"},{"key":"2677_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545\u2013557. https:\/\/doi.org\/10.1016\/S0140-6736(15)00986-1","journal-title":"Lancet"},{"key":"2677_CR25","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T et al (2023) NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 402:1272\u20131281. https:\/\/doi.org\/10.1016\/S0140-6736(23)01366-1","journal-title":"Lancet"},{"key":"2677_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655. https:\/\/doi.org\/10.1097\/00000421-198212000-00014","journal-title":"Am J Clin Oncol"},{"key":"2677_CR27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Liti\u00e8re S et al (2016) RECIST 1.1\u2014standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur J Cancer 62:138\u2013145. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.082","journal-title":"Eur J Cancer"},{"key":"2677_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.amjsurg.2009.08.041","volume":"200","author":"I Bhatti","year":"2010","unstructured":"Bhatti I, Peacock O, Lloyd G et al (2010) Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 200:197\u2013203. https:\/\/doi.org\/10.1016\/j.amjsurg.2009.08.041","journal-title":"Am J Surg"},{"key":"2677_CR29","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1007\/s00268-016-3491-4","volume":"40","author":"K Haruki","year":"2016","unstructured":"Haruki K, Shiba H, Shirai Y et al (2016) The C-reactive protein to albumin ratio predicts long-term outcomes in patients with pancreatic cancer after pancreatic resection. World J Surg 40:2254\u20132260. https:\/\/doi.org\/10.1007\/s00268-016-3491-4","journal-title":"World J Surg"},{"key":"2677_CR30","doi-asserted-by":"publisher","first-page":"12525","DOI":"10.1007\/s13277-016-5122-y","volume":"37","author":"M Wu","year":"2016","unstructured":"Wu M, Guo J, Guo L et al (2016) The C-reactive protein\/albumin ratio predicts overall survival of patients with advanced pancreatic cancer. Tumour Biol 37:12525\u201312533. https:\/\/doi.org\/10.1007\/s13277-016-5122-y","journal-title":"Tumour Biol"},{"key":"2677_CR31","doi-asserted-by":"publisher","first-page":"8781","DOI":"10.2147\/CMAR.S211363","volume":"11","author":"Z Fan","year":"2019","unstructured":"Fan Z, Fan K, Gong Y et al (2019) The CRP\/albumin ratio predicts survival and monitors chemotherapeutic effectiveness in patients with advanced pancreatic cancer. Cancer Manag Res 11:8781\u20138788. https:\/\/doi.org\/10.2147\/CMAR.S211363","journal-title":"Cancer Manag Res"},{"key":"2677_CR32","doi-asserted-by":"publisher","first-page":"2398725","DOI":"10.1080\/07853890.2024.2398725","volume":"56","author":"K Kitsugi","year":"2024","unstructured":"Kitsugi K, Kawata K, Noritake H et al (2024) Prognostic value of neutrophil to lymphocyte ratio in patients with advanced pancreatic ductal adenocarcinoma treated with systemic chemotherapy. Ann Med 56:2398725. https:\/\/doi.org\/10.1080\/07853890.2024.2398725","journal-title":"Ann Med"},{"key":"2677_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","volume":"108","author":"A Wang-Gillam","year":"2019","unstructured":"Wang-Gillam A, Hubner RA, Siveke JT et al (2019) NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer 108:78\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2018.12.007","journal-title":"Eur J Cancer"},{"key":"2677_CR34","doi-asserted-by":"publisher","first-page":"7420","DOI":"10.1038\/s41598-020-64421-6","volume":"10","author":"YY Su","year":"2020","unstructured":"Su YY, Chiang NJ, Tsai HJ et al (2020) The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: real-world experience in a Taiwanese cohort. Sci Rep 10:7420. https:\/\/doi.org\/10.1038\/s41598-020-64421-6","journal-title":"Sci Rep"},{"key":"2677_CR35","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1186\/s12885-021-08887-1","volume":"21","author":"SJ Park","year":"2021","unstructured":"Park SJ, Kim H, Shin K et al (2021) Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study. BMC Cancer 21:1176. https:\/\/doi.org\/10.1186\/s12885-021-08887-1","journal-title":"BMC Cancer"},{"key":"2677_CR36","doi-asserted-by":"publisher","first-page":"14337","DOI":"10.1002\/cam4.6111","volume":"12","author":"L Procaccio","year":"2023","unstructured":"Procaccio L, Merz V, Fasano M et al (2023) The role of nanoliposomal irinotecan plus fluorouracil\/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Cancer Med 12:14337\u201314345. https:\/\/doi.org\/10.1002\/cam4.6111","journal-title":"Cancer Med"},{"key":"2677_CR37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1159\/000525742","volume":"100","author":"H Yasuoka","year":"2022","unstructured":"Yasuoka H, Naganuma A, Kurihara E et al (2022) Efficacy and safety of the combination of nano-liposomal irinotecan and 5-fluorouracil\/l-leucovorin in unresectable advanced pancreatic cancer: a real-world study. Oncology 100:449\u2013459. https:\/\/doi.org\/10.1159\/000525742","journal-title":"Oncology"},{"key":"2677_CR38","doi-asserted-by":"publisher","first-page":"8717","DOI":"10.3390\/ijms24108717","volume":"24","author":"S Kumar","year":"2023","unstructured":"Kumar S, Gahramanov V, Patel S et al (2023) Evolution of resistance to irinotecan in cancer cells involves generation of topoisomerase-guided mutations in non-coding genome that reduce the chances of DNA breaks. Int J Mol Sci 24:8717. https:\/\/doi.org\/10.3390\/ijms24108717","journal-title":"Int J Mol Sci"},{"key":"2677_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/MPA.0000000000001455","volume":"49","author":"T Macarulla Mercad\u00e9","year":"2020","unstructured":"Macarulla Mercad\u00e9 T, Chen LT, Li CP et al (2020) Liposomal irinotecan + 5-FU\/LV in metastatic pancreatic cancer: subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial. Pancreas 49:62\u201375. https:\/\/doi.org\/10.1097\/MPA.0000000000001455","journal-title":"Pancreas"},{"key":"2677_CR40","doi-asserted-by":"publisher","first-page":"1250136","DOI":"10.3389\/fonc.2023.1250136","volume":"13","author":"A Gupta","year":"2023","unstructured":"Gupta A, De Jesus-Acosta A, Zheng L et al (2023) Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study. Front Oncol 13:1250136. https:\/\/doi.org\/10.3389\/fonc.2023.1250136","journal-title":"Front Oncol"},{"key":"2677_CR41","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12885-018-4605-1","volume":"18","author":"DC Glassman","year":"2018","unstructured":"Glassman DC, Palmaira RL, Covington CM et al (2018) Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC Cancer 18:693. https:\/\/doi.org\/10.1186\/s12885-018-4605-1","journal-title":"BMC Cancer"},{"key":"2677_CR42","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/CAD.0000000000000545","volume":"28","author":"SC Leonard","year":"2017","unstructured":"Leonard SC, Lee H, Gaddy DF et al (2017) Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Anticancer Drugs 28:1086\u20131096. https:\/\/doi.org\/10.1097\/CAD.0000000000000545","journal-title":"Anticancer Drugs"},{"key":"2677_CR43","doi-asserted-by":"publisher","first-page":"464","DOI":"10.21037\/jgo-20-338","volume":"12","author":"A Kasi","year":"2021","unstructured":"Kasi A, McGinnis T, Naik G et al (2021) Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil\/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience. J Gastrointest Oncol 12:464\u2013473. https:\/\/doi.org\/10.21037\/jgo-20-338","journal-title":"J Gastrointest Oncol"},{"key":"2677_CR44","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1756-9966-32-92","volume":"32","author":"G Tonini","year":"2013","unstructured":"Tonini G, Imperatori M, Vincenzi B et al (2013) Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res 32:92. https:\/\/doi.org\/10.1186\/1756-9966-32-92","journal-title":"J Exp Clin Cancer Res"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02677-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02677-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02677-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T01:10:52Z","timestamp":1748481052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02677-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2677"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02677-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4821530\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has any potential conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}